title: Enhanced boron uptake in RG 2 rat gliomas by electropermeabilization in vivo--a new possibility in boron neutron capture therapy.
abstract: Accumulation of boron in tumor tissue is an indispensable requirement for boron neutron capture therapy and it is important that the uptake is as high as possible. In this work we have studied the influence of electropermeabilization in vivo on the uptake of boron in normal and RG 2 glioma bearing Fischer 344 rats. Two different boron compounds, a sulfhydryl boron hydride (BSH) and a boronated porphyrin (BOPP), have been investigated. The rats were infused intravenously during 5 min with 175 micrograms BSH/g body weight or 12 micrograms BOPP/g body weight. Two electrodes were placed 5 mm apart in the brain and electropermeabilization was performed with eight square 400 V pulses at 4 and 7 min after the end of the infusion. After 6 h the animals were killed, and the boron content in the tumors and the surrounding brain was measured with neutron-activated autoradiography. In electropermeabilized healthy animals the BOPP uptake was low and limited to the electrode lesions, whereas BSH was spread extensively throughout the hemisphere. Rats with gliomas showed doubled (BOPP) to 10-fold (BSH) uptake of boron in the tumor when electropermeabilization was performed as compared with untreated animals. We conclude that electropermeabilization in the future may provide an interesting possibility to increase the uptake of certain boron compounds before neutron capture therapy.
authors.affiliation: Department of Radiation Physics, Lund University Hospital, Sweden.
authors.forename: C P
authors.initials: CP
authors.lastname: Ceberg
authors.forename: A
authors.initials: A
authors.lastname: Brun
authors.forename: L M
authors.initials: LM
authors.lastname: Mir
authors.forename: B R
authors.initials: BR
authors.lastname: Persson
authors.forename: L G
authors.initials: LG
authors.lastname: Salford
mesh_terms: D000818:Animals; D001894:Borohydrides / Q000493:pharmacokinetics; D001895:Boron / Q000493:pharmacokinetics*; D001896:Boron Compounds / Q000493:pharmacokinetics; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*; D002463:Cell Membrane Permeability / Q000502:physiology*; D003905:Deuteroporphyrins / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D004558:Electric Stimulation; D005260:Female; D005910:Glioma / Q000378:metabolism* / Q000532:radiotherapy*; D007275:Injections, Intravenous; D008297:Male; D009368:Neoplasm Transplantation; D051381:Rats; D011916:Rats, Inbred F344; D013438:Sulfhydryl Compounds / Q000493:pharmacokinetics; D000098851:Carboranes
chemical_list: D001894:Borohydrides; D001895:Boron; D001896:Boron Compounds; D003905:Deuteroporphyrins; D013438:Sulfhydryl Compounds; C080251:2,4-(alpha,beta-dihydroxyethyl)deuteroporphyrin IX tetrakiscarborane carboxylate ester; D000098851:Carboranes; C014651:mercaptoundecahydrododecaborate